![Cabaletta Bio](https://i0.wp.com/www.mychesco.com/wp-content/uploads/2021/06/Cabaletta-Bio.jpg?resize=735%2C400&ssl=1)
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) is set to unveil new clinical data on its investigational therapy, CABA-201, at the American College of Rheumatology (ACR) Convergence 2024. The …
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 Read More